Wedell-Wedellsborg Johan bought $44,232 worth of shares (6,455 units at $6.85) (SEC Form 4)

$YMAB
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $YMAB alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Wedell-Wedellsborg Johan

(Last) (First) (Middle)
C/O Y-MABS THERAPEUTICS, INC.
230 PARK AVENUE, SUITE 3350

(Street)
NEW YORK NY 10169

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Y-mAbs Therapeutics, Inc. [ YMAB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
12/11/2023
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/11/2023 P 6,455 A $6.8523(1) 4,559,233 I By WG Biotech ApS(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. This transaction was executed in multiple trades at prices ranging from $6.85 to $6.86. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
2. Reporting Person is the majority owner of WG Biotech ApS and as such has sole voting and dispositive power with respect to such shares.
/s/ Johan Wedell-Wedellsborg 12/12/2023
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $YMAB alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$YMAB

DatePrice TargetRatingAnalyst
11/18/2024$23.00Outperform
Oppenheimer
8/16/2024$20.00Overweight
Cantor Fitzgerald
6/28/2024$21.00Buy
Truist
5/10/2023$5.00 → $13.00Neutral → Outperform
Wedbush
4/3/2023Buy → Neutral
Guggenheim
1/27/2023$4.00Equal-Weight → Underweight
Morgan Stanley
1/5/2023Outperform → Market Perform
Cowen
12/2/2022$23.00 → $5.00Buy → Neutral
BofA Securities
More analyst ratings

$YMAB
Press Releases

Fastest customizable press release news feed in the world

See more
  • Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments

    Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 The Company established two business units in January 2025 aimed to accelerate the clinical development of its Radiopharmaceuticals Platform and optimize the commercial potential of DANYELZACash and cash equivalents of $67.2 million held as of December 31, 2024, reflects $11.4 million Total Annual Cash Investment in the full year 2024Management announces Full Year 2025 guidance around Total Revenue, Operating Expenses, and Cash Investment and First Quarter 2025 guidance around Total Revenue The Company will host a conference call on Tuesday, March 4, 2025, at 8:00 a.m. ET NEW YOR

    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications

    NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the publication of interim data from a Phase 2 clinical trial evaluating naxitamab with granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with relapsed/refractory high-risk neuroblastoma in the journal Nature Communications. The article, titled "The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a

    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025

    NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report results for the fourth quarter and full year 2024 before the market open on Tuesday, March 4, 2025. Y-mAbs will hold a conference call and webcast to discuss these results on Tuesday, March 4, 2025 at 8:00 a.m. ET. To participate in the live conference call, register here. A live audio webcast of the call will be available on the Investor Relations section of

    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

$YMAB
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$YMAB
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$YMAB
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$YMAB
SEC Filings

See more

$YMAB
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • FDA Approval for DANYELZA issued to Y-MABS THERAPEUTICS INC

    Submission status for Y-MABS THERAPEUTICS INC's drug DANYELZA (SUPPL-8) with active ingredient NAXITAMAB-GQGK has changed to 'Approval' on 03/20/2024. Application Category: BLA, Application Number: 761171, Application Classification:

    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

$YMAB
Leadership Updates

Live Leadership Updates

See more
  • Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit

    NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit. "I am pleased to welcome Doug to Y-mAbs as the new DANYELZA Business Unit head," said Michael Rossi, President and Chief Executive Officer. "We believe Doug's extensive experience leading pharmaceutical commercialization and operations on a global scale will be instrumental in our co

    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

    NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28, 2024. Mr. Pfreundschuh will report to Mike Rossi, President and Chief Executive Officer. "Y-mAbs is at a critical inflection point as we continue to gain U.S. commercial traction with DANYELZA® while simultaneously advancing the development of our differentiated Self-Assembly DisAssembly Pre

    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer

    NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Norman LaFrance, M.D. as Chief Development Officer. "We are thrilled to welcome Dr. LaFrance to Y-mAbs," Mike Rossi, President and Chief Executive Officer. "Norman has an impressive track record in the research, development and commercialization of radiotherapeutics, molecular imaging, diagnostic and therapeutic products. With his deep expertise in develop

    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

$YMAB
Financials

Live finance-specific insights

See more
  • Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments

    Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 The Company established two business units in January 2025 aimed to accelerate the clinical development of its Radiopharmaceuticals Platform and optimize the commercial potential of DANYELZACash and cash equivalents of $67.2 million held as of December 31, 2024, reflects $11.4 million Total Annual Cash Investment in the full year 2024Management announces Full Year 2025 guidance around Total Revenue, Operating Expenses, and Cash Investment and First Quarter 2025 guidance around Total Revenue The Company will host a conference call on Tuesday, March 4, 2025, at 8:00 a.m. ET NEW YOR

    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025

    NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report results for the fourth quarter and full year 2024 before the market open on Tuesday, March 4, 2025. Y-mAbs will hold a conference call and webcast to discuss these results on Tuesday, March 4, 2025 at 8:00 a.m. ET. To participate in the live conference call, register here. A live audio webcast of the call will be available on the Investor Relations section of

    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments

    Reported Total DANYELZA net product revenues of $18.5 million for the third quarter of 2024Entered into exclusive license and distribution agreement with Nobelpharma for DANYELZA in Japan recognizing an upfront payment of $2.0 million in the fourth quarter of 2024Achieved extension of primary DANYELZA U.S. patent through February 2034Continued geographic expansion of DANYELZA with new market revenues recorded in the third quarter from TurkeyManagement reiterates Full Year 2024 guidance around Total Net Revenue, Operating Expenses, and Cash Flow Investment The Company will host a conference call on Friday, November 8, 2024, at 8:00 a.m. ET NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Y-

    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

$YMAB
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more